NovalGen appoints Prof. David Venables to the Board of Directors
- A highly experienced industry executive who brings a wealth of leadership and drug development experience -
London, United Kingdom, 03 May, 2023 – NovalGen Ltd (“NovalGen”), a biopharmaceutical company developing breakthrough cancer therapies, alongside a disruptive auto-regulation platform, today announces the appointment of Prof. David Venables as Non-Executive Director to its Board, effective May 2023.
“We are very pleased to welcome David to NovalGen. David is an exceptional and highly experienced industry executive who will bring a wealth of leadership and drug development experience, and he will be an asset to our Board of Directors,” said Professor Amit Nathwani, Founder and CEO of NovalGen. “NovalGen is at a transformational stage in its development as we progress our lead product through the clinic as well as drive our pre-clinical programmes, including our first-in-class half-life extended T cell engager targeting ROR-1 with autoregulation capability, which demonstrates the inherent value in both our pipeline and our technology base.”
Prof. David Venables has three decades of experience as a serial biotech entrepreneur having taken companies from creation through to acquisition or IPO and taken products from development through to commercial launch. He is currently Founding CEO of Laverock Therapeutics, Board member of Axol Bioscience, and mentor to a number of start-ups. David has held CEO or Senior Executive roles in AskBio, Synpromics, Nightstar, Anatara Lifesciences, Ark Therapeutics, Valneva. He is Honorary Professor at Edinburgh University and holds a PhD in Bioprocess Engineering from the University of Surrey.
- Ends -
Tel.+44(0207) 139 8639
NovalGen is a privately held clinical stage immuno-oncology company developing breakthrough bispecific therapies that can safely harness the immune system to fight cancer, with the aim of creating life-saving new treatments for people with cancer. Alongside this, we are building out our auto-regulation platform that can be applied to a range of therapeutic indications heralding a new era of self-regulating drugs.
Our dedicated team of experienced scientists, physicians and professionals are passionate about building a pipeline of disruptive and differentiated products tailored to the needs of the patient.
The company’s lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematologic malignancies and solid tumors using our breakthrough bispecifics technology.